215 related articles for article (PubMed ID: 8823337)
21. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
22. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors.
Recchia F; Accorsi P; Bonfini T; De Filippis S; Grimaldi M; Corrao G; Rosselli M; Amiconi G; Iacone A; Rea S
J Interferon Cytokine Res; 2000 Feb; 20(2):171-7. PubMed ID: 10714552
[TBL] [Abstract][Full Text] [Related]
24. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
25. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
[TBL] [Abstract][Full Text] [Related]
26. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
27. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
28. Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.
Zimmerman TM; Mick R; Myers S; Bender JG; Lee WJ; Williams SF
Bone Marrow Transplant; 1995 Jun; 15(6):923-7. PubMed ID: 7581092
[TBL] [Abstract][Full Text] [Related]
29. Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections.
Lazarus HM; Haynesworth SE; Gerson SL; Caplan AI
J Hematother; 1997 Oct; 6(5):447-55. PubMed ID: 9368181
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
31. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
[TBL] [Abstract][Full Text] [Related]
32. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
[TBL] [Abstract][Full Text] [Related]
33. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections.
Webb IJ; Eickhoff CE; Elias AD; Ayash LJ; Wheeler CA; Schwartz GN; Demetri GD; Anderson KC
Transfusion; 1996 Feb; 36(2):160-7. PubMed ID: 8614968
[TBL] [Abstract][Full Text] [Related]
35. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
[TBL] [Abstract][Full Text] [Related]
36. Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF.
Lamy T; Drenou B; Grulois I; Leberre C; Dauriac C; Amiot L; Godard M; Fauchet R; LePrise PY
Ann Hematol; 1994 Dec; 69(6):297-302. PubMed ID: 7993937
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization.
Bertolini F; Lanza A; Peccatori F; Zibera C; Gibelli N; Perotti C; Da Prada GA; Torretta L; Cocorocchio E; Martinelli G; Robustelli della Cuna G
Ann Oncol; 1998 Aug; 9(8):913-6. PubMed ID: 9789616
[TBL] [Abstract][Full Text] [Related]
38. Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest.
Dettke M; Greinix HT; Kalhs P; Kührer I; Worel N; Höcker P
Transfusion; 2001 May; 41(5):681-6. PubMed ID: 11346706
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
